Sectors - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pharma/ The leading site for news and procurement in the pharmaceutical industry Tue, 23 Jul 2024 12:35:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.1 https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png Sectors - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pharma/ 32 32 Cellipont Bioservices’ Cell Therapy Manufacturing Facility, Texas, US https://www.pharmaceutical-technology.com/projects/cellipont-bioservices-facility-houston/ Tue, 23 Jul 2024 13:10:01 +0000 https://www.pharmaceutical-technology.com/?post_type=projects&p=167095 Hymecromone by Halo Biosciences for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/#respond Mon, 05 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/feed/ 0 PF-03463275 by Pfizer for Cognitive Impairment Associated With Schizophrenia (CIAS): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/pf-03463275-pfizer-cognitive-impairment-associated-with-schizophrenia-cias-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/pf-03463275-pfizer-cognitive-impairment-associated-with-schizophrenia-cias-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/pf-03463275-pfizer-cognitive-impairment-associated-with-schizophrenia-cias-likelihood-of-approval/feed/ 0 Ciclopirox by ATLAS Molecular Pharma for Porphyria (Erythropoietic Protoporphyri): Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/ciclopirox-atlas-molecular-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/ciclopirox-atlas-molecular-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/#respond Mon, 05 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/ciclopirox-atlas-molecular-pharma-porphyria-erythropoietic-protoporphyri-likelihood-of-approval/feed/ 0 Gefurulimab by Alexion Pharmaceuticals for Proteinuria: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/gefurulimab-alexion-pharmaceuticals-proteinuria-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/gefurulimab-alexion-pharmaceuticals-proteinuria-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/gefurulimab-alexion-pharmaceuticals-proteinuria-likelihood-of-approval/feed/ 0 Caficrestat by Applied Therapeutics for Cardiomyopathy: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-cardiomyopathy-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-cardiomyopathy-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/caficrestat-applied-therapeutics-cardiomyopathy-likelihood-of-approval/feed/ 0 Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/alimta-eli-lilly-and-co-chordoma-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/alimta-eli-lilly-and-co-chordoma-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/alimta-eli-lilly-and-co-chordoma-likelihood-of-approval/feed/ 0 Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-gaucher-disease-type-iii-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-gaucher-disease-type-iii-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/venglustat-malate-sanofi-gaucher-disease-type-iii-likelihood-of-approval/feed/ 0 OMT-28 by OMEICOS Therapeutics for Mitochondrial Myopathy: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/omt-28-omeicos-therapeutics-mitochondrial-myopathy-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/omt-28-omeicos-therapeutics-mitochondrial-myopathy-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/omt-28-omeicos-therapeutics-mitochondrial-myopathy-likelihood-of-approval/feed/ 0 LIOCYXM-004 by Lion TCR for Hepatocellular Carcinoma: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/liocyxm-004-lion-tcr-hepatocellular-carcinoma-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/liocyxm-004-lion-tcr-hepatocellular-carcinoma-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/liocyxm-004-lion-tcr-hepatocellular-carcinoma-likelihood-of-approval/feed/ 0